Abstract Outcome of patients with multiple myeloma (MM) has greatly improved with the use of autologous stem cell transplantation (ASCT) and new agents, such as immunomodulatory drugs (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib). When compared to conventional chemotherapy, high-dose melphalan with ASCT significantly improved response rates and progression-free survival, while overall survival benefit was not consistent across all trials. ASCT is considered the standard treatment for patients who are younger than 65 years and who do not have limiting comorbidities. New, effective agents have been introduced as part of induction, consolidation and maintenance treatments within ASCT and in combinations with chemotherapy for patients not eligible for ASCT. The remarkable results obtained with these regimens are questioning the role of ASCT for newly diagnosed MM patients. This article aims to delineate the role of ASCT in the era of novel agents based on the results of recent clinical trials.
Introduction
Autologous stem cell transplantation (ASCT) is the standard treatment for newly diagnosed multiple myeloma (MM) patients younger than 65 years and/or eligible for high-dose chemotherapy. Before the introduction of novel agents, such as immunomodulatory drugs (IMiDs; thalidomide and lenalidomide) and proteasome inhibitors (bortezomib), high-dose melphalan with ASCT significantly improved response rates and progression-free survival (PFS) in comparison with conventional chemotherapy, with conflicting results in terms of overall survival (OS) [1] [2] [3] [4] . Newer agents were later incorporated both in the transplant and nontransplant settings, and significantly improved patient outcome [5] . The depth and duration of response obtained with these new approaches correlated with a PFS benefit and, in several studies, also with an OS improvement. This was evident in both young patients receiving ASCT, and elderly patients receiving conventional chemotherapy in combination with new agents [6] [7] [8] [9] [10] . It has been suggested that the optimal treatment strategy should aim at achieving sustained complete response (CR) [11] . Yet, long-term control of the disease has been shown also in patients not achieving high-quality responses, which may reflect changes in host immune status or a clonal heterogeneity of the disease at diagnosis. Thus patients may also benefit from a less intensive treatment, that can be able to control, if not eradicate, the disease. The remarkable results obtained in the non-transplant setting questioned the role of ASCT for newly diagnosed MM patients. On the other hand, there is increasing evidence that the selective pressure of treatment may be responsible for emergence of different MM sub-clones leading to drug resistance at more advanced stages [12] . If this can be confirmed, it could be reasonable to give the most effective and intensive treatment, that is ASCT, at the early phases of disease, when the probability of reaching long-lasting remissions is higher.
This article aims to delineate the role of ASCT in the era of novel agents based on the results of recent clinical trials.
New Agents in the Transplant Setting
Novel agents have been incorporated in the pre-transplant induction and post-transplant consolidation and maintenance regimens.
Induction Regimens
Vincristine-doxorubicin-dexamethasone (VAD) was used for many years as pre-transplant induction therapy, inducing an overall response rate (ORR) of 54 % with a CR rate of 2 % [13] . Novel agents (thalidomide and bortezomib) were then tested in combination with dexamethasone as induction regimens before ASCT. Thalidomide plus dexamethasone (TD) increased response rates in comparison with VAD or thalidomide alone: the at least very good partial response (VGPR) rate was 30 % with TD versus 15 % with VAD (P = 0.003) [14] ; the ORR was 72 % with TD versus 36 % with thalidomide alone [15] . Similarly, bortezomib plus dexamethasone (VD) showed an ORR of 78 % in comparison with 63 % with VAD (P \ 0.001) [16] . Two randomized phase III trials evaluated a short course of lenalidomide and dexamethasone (Rd) as induction before ASCT, showing an ORR of 76 %, including 29 % of patients achieving at least a VGPR [17, 18] .
Better results were achieved with three-drug combinations including thalidomide or bortezomib plus conventional chemotherapeutic agents, such as doxorubicin and cyclophosphamide [13, 19, 20] . A significant improvement in ORR in comparison with VAD was reported with doxorubicin in combination with thalidomide-dexamethasone (TAD) (88 vs. 79 %, P = 0.005) [19] and doxorubicin in combination with bortezomib and dexamethasone (PAD) (78 vs. 54 %, P \ 0.001) [13] . Cyclophosphamide in combination with thalidomide-dexamethasone (CTD) significantly enhanced the ORR in comparison with cyclophosphamide-VAD (83 vs. 71 %, P \ 0.0001) [20] .
The three-drug combination bortezomib-thalidomidedexamethasone (VTD) was compared with TD and multiagent chemotherapy [21, 22] . A significant improvement in the CR rate was detected with VTD compared with TD (35 vs. 14 %, P = 0.0001) and with multi-agent chemotherapy (35 vs. 21 %, P = 0.01) [21] . Another study compared the triplet VTD with TD and showed a higher CR rate with the three-drug regimen (31 vs. 11 %, P \ 0.001) [22] . A recent phase 2 trial showed a promising VGPR rate of 58 % after induction with bortezomib-lenalidomide-dexamethasone (VRD) [23] .
Two meta-analyses of data from phase III studies in ASCT-eligible patients with previously untreated MM demonstrated that bortezomib-containing induction regimens results in a significantly improved ORR compared with non-bortezomib-containing regimens [24, 25] .
Two phase II studies did not show significant advantages with four-drug bortezomib-based regimens in comparison with three-drug combinations [26, 27] .
In all the trials previously reported, ASCT further improved the depth of response as shown in Table 1 . It is difficult to estimate how the response rate achieved with induction impact on the efficacy of transplant. Trials published in the ASCT setting showed that the achievement of a high quality response (CR) after ASCT correlates with prolonged PFS and OS [6, [8] [9] [10] [11] . Data available suggest that the higher the cytoreduction obtained with the induction regimen and the subsequent transplantation, the longer the PFS and OS of patients. Table 2 reports safety data of selected induction regimens.
Consolidation Regimens
In the past, a second ASCT was administered to consolidate the response achieved after a first course of highdose melphalan followed by ASCT. Before the introduction of novel agents, several trials showed a prolonged event-free survival (EFS) with double ASCT versus single ASCT [28] [29] [30] . Results of a subgroup analysis of one of those trials, reported an improved OS only in patients achieving less than a VGPR after the first ASCT [28] . The role of double ASCT in the era of novel agents is not yet defined. In the HOVON-65/GMMG-HD4 study, patients were randomized to receive induction with PAD versus VAD followed by ASCT. Per protocol, one or two cycles of high-dose melphalan were planned. A subgroup analysis showed that in patients who received single ASCT, the 5-year OS was 55 % in both PAD and VAD arms (P = 0.39), while in those who received tandem ASCT the 5-year OS was 70 % with PAD and 55 % with VAD (P = 0.07) [13] . The main limitation of this study lies in the fact that patients were not randomized to receive either tandem or single ASCT, but the choice was dependent on country practice [13] . Post-ASCT consolidation with bortezomib and IMiDs is currently under evaluation. In a randomized phase III trial, bortezomib was compared with no consolidation therapy in bortezomib naïve patients [31] . The progression-free survival (PFS) from randomization was 27 months for the bortezomib group and 20 months for the control group (P = 0.05), while no difference in OS was seen [31] . In another trial, VTD consolidation was administrated in patients achieving at least a VGPR after double ASCT. This strategy further improved the depth of response: the CR rate increased from 15 to 49 % and molecular remission rate increased from 3 to 18 % [8, 32] . Of note, the two previous studies included newly diagnosed patients who did not receive novel-agent based induction. A consolidation approach using the same regimens employed during induction (VTD vs. TD) was assessed after double ASCT [33] . VTD consolidation increased the CR/nCR rate from 63 to 73 %; most of the patients who improved to CR after VTD consolidation had achieved at least a VGPR after transplantation. The 3-year PFS was superior with VTD in comparison with TD (60 vs. 48 %, P = 0.042) [33] . Similarly, a recently published trial showed an improvement in post-ASCT response rate with VRD consolidation (VGPR 70 % after ASCT to 87 % after consolidation); as in the previous study, the same regimen was administered as pre-transplant induction [23] . Four cycles of lenalidomide-prednisone have been adopted as consolidation after double ASCT in patients receiving PAD induction. This approach increased the CR rate from 33 to 48 %; also in this study, the major benefit was noticed in patients who achieved VGPR after transplantation [34] . These data show that intensification with bortezomib and/ or IMiDs improves response rates, and the improvement was mainly seen in patients with sensitive disease. The total therapy (TT) study evaluated the impact of the addition of thalidomide (TT2) or bortezomib (TT3) to a multiagent chemotherapy and high-dose melphalan program supported by double ASCT [35] . In this TT study, novel agents were administered both in the pre-transplant and in the post-transplant settings. In the TT3 the cumulative frequency of CR increased during the different treatment phases reaching 56 % at 2 years [36, 37] .
Maintenance Regimens
The optimal maintenance regimen should aim at prolonging the remission duration without affecting the patient's quality of life. Maintenance treatments with alkylating agents, steroids or interferon were tested in the pre-novel agents' era [38] [39] [40] [41] . In one study, maintenance with prednisone every other day improved PFS and OS [38] yet, in another study, no benefit was seen with single-agent dexamethasone [39] .
In six different randomized trials, thalidomide maintenance was used post-ASCT: thalidomide-based maintenance arm was compared with alpha-interferon, dexamethasone, pamidronate, prednisone, or observation in the different trials [19, 35, [42] [43] [44] [45] . A recent meta-analysis showed a reduced risk of progression (HR 0.64, P \ 0.001) and death (HR 73, P = 0.002) with thalidomide maintenance [46] . However, a significant rate of grade 3-4 neuropathy (7-19 %) limited the long-term use of this drug (the rate of discontinuation reached 52 %) [47] . The lack of tolerability of long-term use of thalidomide likely resulted from the doses used in the source studies. These data suggest that continuous therapy with thalidomide is not feasible. Only one trial evaluated post-ASCT bortezomib maintenance. Patients randomized to PAD or VAD induction followed by ASCT received bortezomib or thalidomide maintenance, respectively. In a landmark analysis, bortezomib maintenance significantly improved the CR/nCR rate from 31 to 49 % and reduced the risk of progression (P = 0.04) and death (P = 0.05). The rate of grade 3-4 peripheral neuropathy was 5 % with bortezomib maintenance and 8 % with thalidomide maintenance, the incidence of grade 3-4 infections was 24 and 18 % in the two groups, respectively [13] . These data should be interpreted with caution considering that patients received different induction regimens (patients randomized to PAD induction received bortezomib maintenance, patients randomized to VAD induction received thalidomide maintenance). Three trials evaluated lenalidomide maintenance after ASCT [17, 47, 48] . In two trials, lenalidomide was employed after ASCT in newly diagnosed patients who received VAD or novel agent-based combinations at induction [47, 48] ; in the IFM0502 trial, consolidation with lenalidomide was administered after ASCT, and lenalidomide was then given for up to 2 years [47] ; whereas, in the CALGB 100104 trial no consolidation was planned and lenalidomide maintenance was continued until progression [48] . In the GIMEMA MMRV-209 trial, all patients received induction with Rd, afterwards they were randomized to consolidation with ASCT or no ASCT, and finally to lenalidomide maintenance or no maintenance [17] . The median follow-up period of these three trials was different (range 18-51.2 months) and this further limits the comparison of the results. Despite the differences in the trial designs and treatments, a significant reduction in the risk of progression was reported with lenalidomide maintenance compared with no maintenance (HR range 0.47-0.50) [17, 47, 48] . The CALGB 1000104 trial also showed a significant reduction in the risk of death [48] . The main grade 3-4 adverse events during maintenance with lenalidomide were neutropenia (23-51 %), and infections (6-13 %). Lenalidomide maintenance raised some concern about second primary malignancies (SPM). The incidence of SPM with lenalidomide maintenance was 4.3-8 vs. 2.6-4.3 % with placebo/no maintenance [17, 47, 48] . The use of lenalidomide after high-dose melphalan and with oral melphalan could be a possible explanation for the increased incidence of SPM, as suggested by the results of a recent meta-analysis [49] . In the different studies, however, the advantage associated with lenalidomide maintenance seems to outweigh the risk of SPM.
Non-Transplant Setting
Impressive results were achieved also with novel agents used for the treatment of elderly patients not eligible for ASCT. This provided the rationale to compare novel agentbased regimens with the more intensive approach ASCT, commonly associated with a higher rate of toxicity. Here follows a brief description of the most common regimens including novel agents adopted in the non-transplant setting. A meta-analysis of six randomized trials comparing melphalan-prednisone-thalidomide (MPT) with melphalan-prednisone (MP) improved the median PFS (20.3 vs. 14.9 months, P \ 0.0001) and OS (39.3 vs. 32.7 months, P = 0.004) with MPT [50] . The combination bortezomibmelphalan-prednisone (VMP) improved the median time to progression (24 vs. 16.6 months, P \ 0.001) and OS (56.4 vs. 41 months, P \ 0.001) in comparison with MP [51, 52] . A more intensive regimen including two novel agents was explored in a phase III trial. VMP plus thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) was compared with VMP alone. The 3-year PFS (56 vs. 41 %, P = 0.008) and the 5-year OS (61 vs. 51 %, P = 0.01) were significantly improved with the four-drug combination [53, 54] . In another study bortezomibthalidomide-prednisone (VTP) vs. VMP inductions were followed by VT or bortezomib-prednisone (VP) maintenance. The median PFS was 32 months for VMP and 33 months for VTP (P = 0.09). VMP significantly prolonged the median OS in comparison with VTP (63 vs. 43 months; P = 0.01) [55, 56] . Melphalan-prednisonelenalidomide followed by lenalidomide maintenance (MPR-R) prolonged the median PFS by 17 months in comparison to MPR and MP alone (31 vs. 14 vs. 13 months, P \ 0.001), highlighting the impact of post-induction maintenance in elderly patients [57] ; no differences between MPR without maintenance and MP were noticed. Continuous treatment with lenalidomide and dexamethasone showed prolonged PFS and OS in comparison with MPT [58] . Tables 3 and 4 present efficacy and safety data of selected regimens in the non-transplant setting.
Does the Introduction of Novel Agents Challenge the Role of Transplantation?
The first trial that tried to answer this question compared MPT versus reduced-intensity ASCT in an elderly population of patients. Patients randomized to reduced-intensity ASCT received induction with VAD and no novel agent was administered upfront, which was a limitation of that study. In addition, a higher rate of toxic deaths was reported during the first 3 months of treatment in the reduced-intensity ASCT arm (therefore related to the induction regimen and not to ASCT itself) and this may have negatively affected the final results. MPT showed a significant reduction in the risk of progression (HR 0.54, P = 0.0002) and the risk of death (HR 0.59, P = 0.027) in comparison with reduced intensity ASCT [59] . Despite its limitations, this study questioned the role of ASCT in the era of new drugs. The comparison of studies conducted in patients younger than 65 years versus those conducted in patients older than 65 years is however difficult. Recently, the first prospective randomized trial comparing combination chemotherapy including novel agents versus ASCT has been performed. Patients received Rd induction therapy and were then randomized to MPR or tandem ASCT. The median PFS was significantly longer for patients who were randomized to tandem ASCT than for those randomized to MPR (43.0 vs. 22.4 months, P \ 0.001). Tandem ASCT also improved the 4-year OS rate (81.6 vs. 65.3 %, P = 0.02) [17] . In a similar study, 390 patients received Rd induction regimen and were then randomized to receive tandem ASCT or cyclophosphamide-lenalidomide-dexamethasone, followed by lenalidomide or lenalidomide plus prednisone maintenance therapy. Preliminary results showed a reduced risk of progression for patients who received ASCT (3-year PFS: 60 vs. 38 %, P = 0.003), with no advantage in terms of OS at the last follow-up [18] . Two ongoing large studies are currently enrolling patients. In the IFM/DFCI2009 study, 1000 patients are receiving VRD induction and are then randomized to continue VRD treatment or to receive ASCT plus VRD consolidation. Subsequently, patients will receive lenalidomide maintenance (CT.gov NCT01191060; NCT01208662). In the EMN02 study 1500 patients are receiving VCD induction and are then randomly assigned to VMP or ASCT, and further randomized to receive consolidation/no consolidation with VRD, followed by lenalidomide maintenance (CT.gov NCT01208766). Results of these two trials will clarify whether transplant will be superior to bortezomiblenalidomide and/or bortezomib-melphalan-based combinations.
In the majority of the previously described trials, patients who did not receive ASCT upfront will receive ASCT at relapse. These trials will therefore also try to define the best timing of ASCT, upfront or at first relapse. Before the introduction of novel agents, several randomized trials confirmed the PFS benefit with early ASCT in comparison with conventional chemotherapy. However, in three randomized studies, OS was similar whether ASCT was performed early or as salvage therapy at relapse [2] [3] [4] . Despite similar OS (64.6 vs. 64 months, P = 0.92), early ASCT improved the average time without symptoms (27.8 vs. 22.3 months) and reduced treatment-related toxicities and discontinuation compared with late ASCT in one trial [3] . Yet, in most of these trials, patients in the control arm did not have full access to novel agents, and these questions need to be addressed in trials including novel agents.
In the era of new agents, to date only the results of two trials comparing early versus delayed ASCT are available. A recent pooled analysis including these two randomized trials was performed. The pooled analysis showed an improvement in PFS (median 42 vs. 24 months, P \ 0.001) and OS (4-year 83 vs. 68 %, P = 0.012) in patients receiving early ASCT [60] .
Conclusions and Future Perspectives
The introduction of effective regimens including bortezomib and IMiDs has greatly improved the outcome observed with ASCT in young MM patients. The data from the prospective trials performed to date suggest that the best available strategy to achieve high CR rate, to prolong response duration and survival consists in a sequential approach including induction with three-drug, bortezomibbased combinations followed by ASCT and consolidation/maintenance with IMiDs or proteasome inhibitors. A major drawback of the majority of the previously described trials is the fact that none of them was powered to assess OS. OS results may be affected by effective second-line therapy that dilutes the ability to dissect out the role of transplant versus no transplant. The impact of ASCT versus no ASCT could be also partly related to the number of therapeutic options available in different parts of the world. Obviously, in the setting of limited treatment options, ASCT may play a more important role than in parts of the world where patients have a wider variety of treatments. Despite these considerations, available results suggest that upfront ASCT still remains a necessary component of therapy if compared with conventional chemotherapy plus IMiDs. The role of ASCT in comparison with bortezomib plus chemotherapy or IMiDs is currently under evaluation. The results of ongoing studies (IFM/DFCI2009 and EMN02) are awaited and will help clarify the role of ASCT in the era of new drugs.
